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ABSTRACT
As a member of the p53 gene family, p73 regulates cell cycle arrest, apoptosis, 
neurogenesis, immunity and inflammation. Recently, p73 has been shown to 
transcriptionally regulate selective metabolic enzymes, such as cytochrome c oxidase 
subunit IV isoform 1, glucose 6-phosphate dehydrogenase and glutaminase-2, 
resulting in significant effects on metabolism, including hepatocellular lipid 
metabolism, glutathione homeostasis and the pentose phosphate pathway. In order 
to further investigate the metabolic effect of p73, here, we compared the global 
metabolic profile of livers from p73 knockout and wild-type mice under both control 
and starvation conditions. Our results show that the depletion of all p73 isoforms 
cause altered lysine metabolism and glycolysis, distinct patterns for glutathione 
synthesis and Krebs cycle, as well as an elevated pentose phosphate pathway and 
abnormal lipid accumulation. These results indicate that p73 regulates basal and 
starvation-induced fuel metabolism in the liver, a finding that is likely to be highly 
relevant for metabolism-associated disorders, such as diabetes and cancer.
INTRODUCTION
The transcription factor p73 belongs to the p53 gene 
family and shares structural and functional homology to the 
tumor suppressor p53 [1–9]. Due to alternative promoters 
near the N-terminus, p73 is mainly transcribed in two types 
of isoforms, the transcriptionally active TAp73 and the 
dominant negative ΔNp73 [10, 11]. TAp73 isoforms act as 
tumor suppressors by inducing apoptosis, cell cycle arrest 
and maintaining genomic stability, whereas ΔNp73 variants 
counteract the tumor-suppressor activity of p73 and p53 
by directly binding to the p53 response element or by the 
formation of inactive oligomers [12–15]. p73 knockout (KO) 
mice exhibit severe neurological and immunological defects 
due to the absence of all p73 isoforms [16]. Mice lacking 
TAp73 show infertility, formation of spontaneous tumors and 
elevated sensitivity to chemical carcinogens, highlighting 
the tumor suppressive function of TAp73 [17]. Conversely, 
ΔNp73 KO mice are fertile with signs of moderate 
neurodegeneration and, interestingly, diminished tumor 
development [18]. However, the TP73 gene is rarely mutated 
or deleted in human cancer, suggesting a more complicated 
scenario for the role of p73 in cancer [1, 19]. Accordingly, the 
balance between the TAp73 and the ΔNp73 isoforms dictates 
the fate of the individual cell, and the outcome of the tumor.
Besides its tumor-suppressive role, TAp73 has been 
shown to be capable of regulating metabolism [20, 21]. 
For instance, overexpression of TAp73α in Saos-2 cells 
increased mitochondrial activity to boost glutathione 
homeostasis and to elevate the activity of the pentose 
phosphate pathway (PPP) [22]. TAp73 is able to directly 
regulate the transcription of Cox4i1, affecting the function 
of complex IV in mitochondria and resulting in a redox 
imbalance that contributes to premature senescence and 
aging [23, 24]. TAp73 has also a direct effect on the 
serine/glycine biosynthesis. Indeed, metabolic profiling of 
human cancer cells revealed that TAp73 regulates serine 
biosynthesis by transcriptional control of glutaminase-2 
(GLS-2), an enzyme that supports glutathione synthesis 
and enables an effective compensation for an excessive 
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oxidative response [25, 26]. As a consequence, TAp73 
has a profound effect on cellular metabolism in a 
manner similar, but distinct to p53 and p63 [27, 28]. 
In addition to this finding, TAp73 enhances the PPP 
flux via transcriptional activation of a rate-limiting 
enzyme in PPP, the glucose-6-phosphate dehydrogenase 
(G6PD) [29]. These findings are consistent with the 
current understanding on the role of TAp73 as a potent 
tumor suppressor [30] indicating that TAp73 mounts an 
anti-senescence metabolic response [31]. Accordingly, 
recently published metabolomics studies of cancer cells 
revealed that TAp73 promotes anabolism to counteract 
cellular senescence rather than to support proliferation 
[32]. Hence, the newly revealed, exciting role of p73 in 
metabolism is complex and requires more follow-up in 
vitro and in vivo studies.
Our previous study showed that p73 regulates 
autophagy by transcriptional activation of autophagy-
related protein 5 (ATG5) and pointed out the importance 
of p73 in the hepatocellular lipid metabolism [33]. 
To investigate the role of p73 in the hepatocellular 
metabolism in vivo, we performed metabolic profiling of 
the livers from both WT and the full p73 KO mice under 
both control and starvation conditions. Our data show 
that p73 depletion results in altered metabolic pathways, 
including lysine and methionine metabolism, glutathione 
homeostasis, PPP, Krebs cycle, and lipid metabolism. In 
contrast to previously published work [29], we observed 
an increased, instead of decreased, PPP flux in the p73 
KO mice, implying the existence of other transcriptional 
factors regulating the G6PD expression.
RESULTS
Different metabolic profiles in WT and 
p73 KO mice
To investigate the role of p73 in starvation-
induced metabolic changes, liver samples from 
both control and starved WT and p73 KO mice were 
collected and prepared for global biochemical profile 
by GC/MS or LC/MS. For each group, 7 individual 
mice for the wild genotype and 4 individual mice for 
the p73 KO genotype were analyzed separately. Mice 
were all littermates, untreated or starved for 24 hours 
before being sacrificed. All these biological replicates 
were immediately stored at –80°C until extracted and 
prepared for analysis. Following statistical analysis 
by 2-way ANOVA and ANOVA contrasts, biochemical 
metabolites showing statistical significance (p ≤ 0.05), 
as well as those approaching significance (0.05 < p < 
0.1), were tabulated and summarized in Table 1. In total, 
347 compounds of known identity were identified in 
this study (Supplementary Table S1). Heat maps of total 
347 metabolites and subgroups are shown in Figure 1 
and Supplementary Figure S1. As expected, starvation 
dramatically altered the metabolism as indicated for 184 
compounds, which exhibited significant change. Overall, 
fasting for 24 hours induced a metabolic program 
consistent with stimulation of autophagy as evidenced 
by increased amino acids, depletion of glycogen, 
and a shift from carbohydrate to lipid metabolism, 
including elevated ketogenesis. A noticeable number 
of metabolites (71) showing significant genotype-based 
differences were detected between the WT and p73 KO 
mice, underlining the importance of p73 both for basal 
and starvation-induced liver metabolism.
Starvation induces a metabolic switch from 
carbohydrate to lipid metabolism [34]. Several 
metabolic pathways are normally upregulated, including 
glycogenolysis, gluconeogenesis, lipolysis, and 
ketogenesis. In our study, depletion of hepatic glycogen 
was observed to a similar extent in both WT and p73 
KO mice after starvation, as evidenced by significant 
reductions in the glycogen degradation products, such 
as maltose, maltotriose, maltotetraose, maltopentaose, 
and maltohexaose suggesting that p73 is not involved 
in glycogenolysis (Supplementary Table S1). Starvation 
for 24 hours induced significant elevations in many free 
amino acids, which is likely attributable to increased 
skeletal muscle protein degradation and subsequent 
uptake of amino acids by the liver for entry into the 
gluconeogenic pathway. Interestingly, starvation-induced 
effects on protein metabolism may be less pronounced 
in p73 KO mice, as many amino acids were elevated to 
a lesser degree as compared to wild-type mice. This is, 
presumably owing, at least partially, to the deficiency of 
autophagy (Supplementary Figure S1) [33]. In addition, 
p73 KO mouse livers showed an increased lipid content 
upon starvation compared to the WT mice (Figure 1C). 
These data suggest that p73 depletion may cause defective 
lipid degradation or utilization, resulting from defective 
autophagy or a decreased rate of β-oxidation. Overall, 
starvation for 24 hours induced a metabolic switch in 
both WT and p73 KO mice and p73 KO mice exhibited 
genotype-based differences in several metabolic pathways 
compared to those of WT mice, which are presented 
below.
Altered lysine and methionine metabolism and 
glutathione synthesis in p73 KO mice
Lysine belongs to the ketogenic amino acids that 
are able to produce ketone bodies in the liver under 
starvation conditions [35]. Ketone bodies include acetone, 
as well as acetoacetate and 3-hydroxybutyrate, both of 
which serve as important fuels for the brain. They are 
produced by breakdown of amino acids or fatty acids 
during prolonged starvation with a low glucose level in 
the blood. Here, intermediates of the lysine metabolism 
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pathway, especially 2-aminoadipate and glutarate were 
much more elevated in p73 KO mice compared to those 
of WT mice upon starvation. Accordingly, the ketone 
body, 3-hydroxybutyrate also showed increased levels in 
the p73 KO mice under starvation condition (Figure 2). 
These findings thus suggest that the expression of enzymes 
involved in the lysine metabolism may be affected by p73 
and the regulation of ketogenesis may differ between WT 
and p73 KO mice under starvation condition.
As an important antioxidant, reduced glutathione 
(GSH) prevents cellular damage caused by reactive 
oxygen species. Once oxidized, GSH readily reacts 
with another reactive glutathione to form glutathione 
disulfide (GSSG) which is then reduced to GSH using 
NADPH. Glutathione can be synthesized from amino 
acids, including glycine, glutamate and methionine-
derived cysteine. Under control conditions, methionine 
levels were reduced while increases in homocysteine and 
cysteine were observed in p73 KO mice as compared 
to those of WT mice. Together with a non-significant 
decrease in GSH and similar levels of GSSG, these 
findings may be suggestive of an attempt to increase 
glutathione synthesis, possibly in response to greater 
glutathione utilization in p73 KO mice (Figure 3). Under 
starvation conditions, an apparent increase in glutathione 
synthesis accompanied by depletions in both reduced 
and oxidized glutathione and a significant elevation in 
the biochemical marker of oxidative stress, cysteine-
glutathione disulfide (Supplementary Table S1). These 
changes are consistent with the oxidative insult associated 
with increased mitochondrial β-oxidation of fatty 
acids during starvation. Interestingly, the subpathway 
producing ophthalmate (produced when 2-aminobutyrate 
is substituted for cysteine and is synthesized by the same 
enzymes as glutathione), a glutathione-like compound 
was much more activated in the p73 KO mice than that 
in the WT mice under starvation conditions as shown by 
increased levels of 2-aminobutyrate, 2-hydroxybutyrate 
and ophthalmate (Figure 3). These findings indicate that 
the enzyme involved in the ophthalmate subpathway is 
possibly regulated by p73. Hence, p73 KO mouse livers 
might exhibit a more oxidative environment compared to 
WT mouse livers.
Differential glycolysis and elevated PPP in p73 
KO mice
As a central metabolite, glucose can be oxidized 
to pyruvate via glycolysis or oxidized via the PPP to 
yield ribose 5-phosphate for nucleic acid synthesis and 
NADPH for reductive processes. In the p73 KO mice, 
increases in glucose, glucose 6-phosphate, and fructose 
6-phosphate were detected under control conditions. 
Downstream metabolites, 3-phosphoglycerate and 
2-phospho-glycerate were unchanged in the p73 KO 
mice, suggesting a distinct impact on glycolysis caused 
by loss of p73 expression (Figure 4). Upon starvation, 
the level of glucose in the liver dropped down in both 
groups of mice due to increased utilization by other 
organs. Interestingly, the levels of 3-phosphoglycerate 
and 2-phosphoglycerate were significantly reduced as 
compared to those of WT mice (Figure 4). Since both 
metabolites are also used to produce serine, which is 
the precursor of cysteine, low levels of those molecules, 
may be suggestive of limited availability of cysteine 
for glutathione synthesis in the p73 KO mice under 
starvation conditions. This again indicates that p73 mice 
probably suffer from oxidative stress.
Table 1: Statistical summary of significant alterations of the metabolites
ANOVA Contrasts Starved / Control p73 KO / WT
WT p73 KO Control Starved
Total biochemicals p ≤ 0.05 118 131 42 37
Biochemicals  
(increased/decreased) 68|50 58|73 31|11 18|19
Total biochemicals 0.05 < p < 0.10 38 34 25 38
Biochemicals  
(increased/decreased) 25|13 20|14 14|11 14|24
Two-Way ANOVA Genotype Main 
Effect
Treatment Main 
Effect
Genotype:Treatment 
Interaction
Total biochemicals p ≤ 0.05 71 184 34
Total biochemicals 0.05 < p < 0.10 35 19 32
Contrasts resulting from 2-way ANOVA shown in the upper table were used to identify the metabolites that differed 
significantly between experimental groups. The lower table shows the numbers of significantly changed metabolites in 
consideration of genotype, treatment, and interaction.
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The second metabolite in glycolysis, glucose 
6-phosphate can be oxidized by G6PD to enter the PPP 
(Figure 4 and Figure 5). Which pathway the glucose 
6-phosphate enters is dependent on the current needs of the 
cell and on the concentration of NADP+ in the cytosol. In 
liver, the PPP is mainly used to metabolize excess glucose 
and to produce NADPH, allowing the maintenance of the 
antioxidant glutathione in its reduced form. TAp73 has 
been shown to enhance PPP activity and to support cell 
proliferation by transcriptional activation of G6PD, the 
rate-limiting enzyme of PPP [29]. Contrary to this report 
[29], and in agreement with our previous data [31, 32], loss 
of p73 expression did not reduce, but rather increased, PPP 
activity as evidenced by several upregulated end products, 
including arabitol, ribose, ribulose and xylulose under 
control conditions (Figure 5). This indicates that other p73 
family members or additional transcription factors might 
also regulate the expression of G6PD. Nevertheless, these 
consistent elevated concentrations of end products point 
to the possibility of reduced hepatic glucose utilization or 
greater NADPH synthesis under non-starvation conditions 
when p73 is lacking. In addition, starvation induced a 
sharper decline in metabolites related to the PPP in p73 
KO mouse livers compared to WT mouse livers. This 
finding might be related to increased PPP activity under 
control conditions, or, alternatively, to a differential 
carbohydrate metabolism when adapting to starvation in 
p73 KO mice. As mentioned above, an elevated PPP has 
important implications for the maintenance of glutathione 
in its reduced state, and, therefore, the response to 
oxidative stress.
Alterations in citrate and krebs cycle 
intermediates in p73 KO mice
The Krebs cycle is a key component of cellular 
respiration for energy production. Several intermediates of 
the Krebs cycle were increased under control conditions 
Figure 1: Heat maps of the metabolites. Liver samples of the control and starved mice were extracted and prepared for the MS 
analysis. The levels of the total 347 metabolites are shown as a heat map in A. Heat maps of the metabolite subgroups, amino acids and 
lipids, are shown in B. and C. The black boxes indicate the extensive changes of the metabolites under different conditions. St.: starvation; 
Cont.: control.
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when p73 is lacking, including citrate, cis-aconitate, 
fumarate, and malate. Notably, citrate showed more than 
16 fold higher concentration in the p73 KO liver compared 
to WT. The increased concentrations of other compounds 
were not as pronounced as the increase of citrate (Figure 6). 
Changes in cycle activity in p73 KO livers under control 
conditions could explain these findings, although the 
directionality of change is difficult to predict from steady-
state measurements. Alternatively, the changes could be due 
to shuttling of citrate from the mitochondria into the cytosol 
for fatty acid synthesis and, subsequently, incorporation into 
triglycerides. Importantly, a high concentration of cytosolic 
citrate allosterically inhibits phosphofructokinase-1, a rate-
limiting enzyme in glycolysis, which may elucidate the 
abnormality in glycolysis and the PPP in p73 KO mice. 
Upon starvation, fumarate and malate were significantly 
reduced in both p73 KO and WT mice, probably due to an 
increased contribution to gluconeogenesis by oxaloacetate. 
In addition, the co-enzyme NAD+ was not significantly 
increased and the level of FAD was reduced in the p73 KO 
mice livers under starvation conditions (Figure 6). Since 
both metabolites are generated by the electron transport 
chain (ETC) for ATP production, these changes point to the 
possibility of reduced ETC activity in livers of p73 KO mice.
DISCUSSION
While autophagy [36–40] has a particular relevance 
in cancer biology [41–43], several indications, already 
suggest that this relationship is affected by p53 and its 
family members [44–50]. Other indirect evidence also 
suggests the same conclusion [51]. For example, p73, 
which strongly affects neuronal [52–55] and cancer 
[56–59] biology, is regulated by its protein degradation 
by the E3 ubiquitin ligase Itch [60–63]. Interestingly, the 
inhibitors of Itch are indeed regulators of autophagy [64].
Our previous work reported that p73 regulates 
autophagy and lipid metabolism in hepatocytes via 
transcriptional activation of ATG5 [33]. Autophagy, a 
highly regulated self-digestion process, is kept at a low 
level to maintain cellular homeostasis. Dysregulated 
autophagy has been shown to be associated with 
neurodegenerative diseases, infections, and cancer [65–67]. 
Autophagy plays a key role in regulating cell survival 
Figure 2: Lysine metabolism. Lysine is an essential amino acid that can contribute to energy production through conversion to the 
ketone bodies, acetoacetate and 3-hydroxybutyrate. A schematic diagram for lysine metabolism is shown in A. Levels of the metabolites 
found in this pathway are shown in B. P values were calculated via 2-way ANOVA contrasts test. * < 0.05; ** < 0.01; *** < 0.001; p values 
between 0.05 and 0.1 are shown as numbers. C. Legends description of box-and-whiskers plot. Y-axis: relative amount of metabolite. 
Metabolites showing significant changes are highlighted in red.
Oncotarget33183www.impactjournals.com/oncotarget
Figure 3: Methionine metabolism and glutathione synthesis. As an important antioxidant, glutathione is synthesized from 
glycine, glutamate and methionine-derived cysteine. A. A schematic diagram of methionine metabolism and the glutathione synthesis 
pathway. Levels of the metabolites found in this pathway are shown in B. GCS: γ-glutamylcysteine synthetase, GS: glutathione synthetase, 
GGT: γ-glutamyltranspeptidase. P values were calculated via 2-way ANOVA contrasts test. * < 0.05; ** < 0.01; *** < 0.001; p values 
between 0.05 and 0.1 are shown as numbers. Y-axis: relative amount of metabolite. Legends descriptions are the same as in Figure 2C. 
Metabolites showing significant changes are highlighted in red.
Figure 4: Glycolysis. As a major catabolic pathway, glycolysis produces ATP by converting glucose to pyruvate, which can then be 
transferred to the mitochondria to enter the Krebs cycle for further energy production. A. A schematic diagram for glycolysis. Levels of 
the metabolites found in this pathway are shown in B. P values were calculated via 2-way ANOVA contrasts test. * < 0.05; ** < 0.01; 
*** < 0.001; p values between 0.05 and 0.1 are shown as numbers. Y-axis: relative amount of metabolite. Legends descriptions are the 
same as in Figure 2C. Metabolites showing significant changes are highlighted in red.
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under starvation conditions by increasing the availability 
of nutrients to maintain energy production [68, 69]. In the 
present study, starvation-induced metabolic changes were 
observed in livers of both WT and p73 KO mice. Some of 
the altered metabolic pathways could be the consequence 
of defective autophagy in liver cells of p73 KO mice. For 
instance, the generally lower levels of amino acids and the 
higher lipid content of p73 KO compared to WT mouse 
liver likely result from reduced autophagy [33]. Moreover, 
autophagy-regulated removal of damaged mitochondria 
could affect the cellular respiration system as well [70].
Based on our in vivo observations, p73, besides 
its role in autophagy, seems to directly affect distinct 
metabolic pathways, including amino acid metabolism, 
glycolysis, PPP, the response to oxidative stress, Krebs 
cycle, and fatty acids metabolism. In the metabolism 
of amino acids, it has been shown that TAp73 
transcriptionally controls a key enzyme of glutaminolysis, 
GLS-2, that favors the conversion of glutamine in 
glutamate, which in turn promotes the serine biosynthetic 
pathway [25]. In line with this finding, the levels of 
glutamate and serine were found to be reduced in livers 
of p73 KO mice when compared with those of WT mice. 
Furthermore, upon starvation, lysine and methionine 
metabolism as well as glutathione synthesis were altered 
in the absence of p73 expression. As lysine degradation 
primarily occurs in the liver and the products of its 
degradation mainly contribute to production of ketone 
bodies, the elevation in these metabolic pathways in livers 
of p73 KO mice under starvation conditions suggests the 
usage of distinct fuels or a lack of energy derived from 
other metabolites. Related to the amino acid metabolism, 
altered glutathione synthesis could be observed in the p73 
KO mice, as the alternative anti-oxidant ophthalmate was 
increased upon starvation, highlighting the potential role 
of p73 in oxidative stress responses.
Under certain conditions, glucose can be diverted 
to the PPP that is important for metabolism of excess 
glucose, for production of NADPH, and for synthesis of 
nucleotides. p53 can inhibit G6PD expression by direct 
interaction with G6PD or can promote G6PD expression 
by the transcriptional activation of its target, TIGAR, 
suggesting important roles of p53 family members 
in the PPP [71, 72]. Recently, it has been reported that 
TAp73 increases PPP flux to promote NADPH and ribose 
synthesis by transcriptional activation of a rate-limiting 
enzyme, the G6PD [29]. Moreover, these authors have 
also shown that depletion of TAp73 reduced the PPP flux, 
which could be rescued by G6PD expression. However, 
our study showed significant increases in glucose and 
several end products of PPP even when expression of 
all p73 isoforms was lacking under control conditions. 
In line with our finding, a more recent study showed no 
difference in the PPP and an increase in glycolysis in 
Figure 5: Pentose phosphate pathway (PPP). The PPP mainly produces NADPH and pentoses. As a rate-limiting enzyme, glucose-
6-phosphate dehydrogenase (G6PD) performs the oxidation of glucose-6-phosphate, the first reaction of the PPP. A. A schematic diagram 
of the PPP. Levels of the metabolites found in this pathway are shown in B. G6PD: glucose-6-phosphate dehydrogenase. P values were 
calculated via 2-way ANOVA contrasts test. * < 0.05; ** < 0.01; p values between 0.05 and 0.1 are shown as numbers. Y-axis: relative 
amount of metabolite. Legends descriptions are the same as in Figure 2C. Metabolites showing significant changes are highlighted in red.
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TAp73β-overexpressing Saos-2 cells [73]. These data 
suggest that the transcriptional control of G6PD is not 
uniquely regulated by TAp73; accordingly we suggested 
also a regulation by p63 [74]. Alternatively, these results 
may even indicate that p73 family members are able to 
inhibit the PPP, and hence act as tumor suppressors, in a 
similar manner as p53.
The significant increase in citrate and other 
intermediates of the Krebs cycle may be a consequence 
of changes in the cycle activity or, alternatively, be 
owing to citrate shuttling from mitochondria to the 
cytosol in p73 KO mice under control conditions. High 
level of citrate in the cytosol of hepatocytes promotes in 
turn fatty acid synthesis, inhibits glycolysis, leading to 
alternative glucose utilization by the PPP under control 
conditions, and, subsequently, contributes to ketogenesis 
under starvation conditions. Moreover, the lower levels 
of NAD+ and FAD in the p73 KO upon starvation also 
point to possible defects in the ETC, since the expression 
of a mitochondrial ETC subunit, cytochrome c oxidase 
subunit IV isoform 1 (Cox4i1), is under the control of 
TAp73 [23]. Notably, reduced ETC activity leads to 
reduced ATP levels, increased ROS production, and 
dependence on glucose, explaining the altered glutathione 
synthesis and distinct glucose utilization observed in 
the p73 KO mice. It is also important to mention that 
these processes are relevant autophagic targets [75–83]. 
Moreover, TAp73 isoforms most likely contribute to the 
regulation of metabolism owing to their transactivation 
domain. However, ΔNp73 isoforms might also be 
involved owing to their dominant-negative property. For 
instance, ΔNp73 isoforms might negatively regulate the 
expression of G6PD and, consequently, elevate PPP in 
p73 KO mice. Furthermore, the p73 isoforms generated 
by different C-terminal splicing events might participate 
in the metabolic regulation as well, since both TAp73 and 
ΔNp73 KO mice show less severe phenotypes compared 
to the total p73 KO mice [16–18].
Cancer cells often modify their metabolism by 
promoting diverse biosynthetic pathways to adapt to 
the environment and to ensure their rapid proliferation 
[84–92]. Besides aerobic glycolysis, the PPP is also 
activated to provide metabolites for nucleotide synthesis 
and NADPH to compensate the oxidative stress in cancer 
cells. As TAp73 is considered as a tumor suppressor, 
our work showing altered glycolysis and upregulated 
Figure 6: Krebs cycle and citrate shuttle. The Krebs cycle is a core process for generating energy in the form of ATP in all aerobic 
organisms. The cyclic pathway begins with the formation of citrate, which can be also transferred from mitochondria into cytosol for fatty 
acid synthesis (citrate shuttle). A. A schematic diagram of the Krebs cycle and citrate shuttle pathways. Levels of the metabolites found in 
these pathways are shown in B. P values were calculated via 2-way ANOVA contrasts test. * < 0.05; ** < 0.01; p values between 0.05 and 
0.1 are shown as numbers. Y-axis: relative amount of metabolite. Legends descriptions are the same as in Figure 2C. Metabolites showing 
significant changes are highlighted in red.
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PPP further implies a metabolic role for p73 in tumor 
suppression. Furthermore, fasting has an anti-aging 
effect and can be used to help fighting against several 
diseases, including diabetes, hypertension, asthma and 
cancer [93]. p73 may therefore play a fundamental role 
in these starvation-induced processes, since p73 has also 
been shown to be involved in aging, inflammation, and 
tumorigenesis [23, 94]. Hence, follow-up studies focusing 
on the different specific pathways are recommended. 
Overall, our in vivo findings in livers showed that p73 
depletion resulted in several altered metabolic pathways 
pointing to the importance of p73 in the basal and 
starvation-induced hepatocellular metabolism.
MATERIALS AND METHODS
Mice
p73 KO mice were generated as previously 
described [16]. Mice were bred and subjected to listed 
procedures under the Project Licence PPL 40/3442 
released from the UK Home Office. The starvation 
experiments with the mice were performed by food 
deprivation for 24 hours with free access to drinking water. 
Liver samples from both WT and p73 KO mice were 
collected and immediately frozen for metabolic analysis.
Metabolic analysis
Both WT and p73 KO mice were either fed ad libitum 
or starved for 24 hours. Liver samples from these mice were 
collected, immediately stored at –80°C until extracted and 
prepared for analysis using a standard solvent extraction 
method. Mass spec analysis was either performed in house 
at the MRC or at Metabolon® (www.metabolon.com). 
The sample preparation process was carried out using the 
automated MicroLab STAR® system (Hamilton Company). 
To purify the small molecules, the protein fraction was 
removed using an organic and aqueous extractions. The 
resulting extract was divided into two fractions, one for 
analysis by liquid chromatography (LC) and one for analysis 
by gas chromatography (GC). The organic solvent was 
removed by placing the samples briefly on a TurboVap® 
(Zymark). Each sample was then frozen and dried under 
vacuum. After drying, samples were then prepared for the 
appropriate instrument, either LC/MS or GC/MS. After log 
transformation and imputation with minimum observed 
values for each group, the comparison of the metabolites 
of each sample was performed. The LC/MS portion of the 
platform was based on a Waters ACQUITY UPLC and a 
Thermo-Finnigan LTQ mass spectrometer, which consisted 
of an electrospray ionization (ESI) source and linear ion-
trap (LIT) mass analyzer. The samples destined for GC/
MS analysis were re-dried under vacuum desiccation for 
a minimum of 24 hours prior to being derivatized under 
dried nitrogen using bistrimethyl-silyl-triflouroacetamide 
(BSTFA). The GC column was 5% phenyl and the 
temperature ramp is from 40° to 300° C in a 16 minute 
period. Samples were analyzed on a Thermo-Finnigan Trace 
DSQ fast-scanning single-quadrupole mass spectrometer 
using electron impact ionization. Compounds were identified 
by comparison to library entries of purified standards or 
recurrent unknown entities. The quality control and curation 
processes were designed to ensure accurate and consistent 
identification of true chemical entities, and to remove 
those representing system artifacts, mis-assignments, and 
background noise. See [22, 31, 32, 74] for further details.
Statistics
The metabolic analysis described above comprises 
347 named compounds. Following 2-way ANOVA 
analysis, contrasts were used to identify metabolites that 
differed significantly between experimental groups. The 
total list of compounds that showed statistical significance 
(p < 0.05), as well as those approaching significance (0.05 
< P < 0.10) were presented in Table 1. The p values for 
each compound, including Pcontrasts, Pgenotype, Ptreatment and 
Pinteraction, are indicated in Supplementary Table S1.
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